2022
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2018
Medicare Cancer Screening in the Context of Clinical Guidelines
Maroongroge S, Yu J. Medicare Cancer Screening in the Context of Clinical Guidelines. American Journal Of Clinical Oncology 2018, 41: 339-347. PMID: 26886947, DOI: 10.1097/coc.0000000000000272.Peer-Reviewed Original ResearchConceptsCancer screeningScreening ratesFee-for-serviceColorectal cancer screening ratesBilling codesCancer screening ratesColorectal screening testsMedicare fee-for-serviceMedicare Part B beneficiariesMonte Carlo permutation methodMedicare FFS populationBeneficiaries per yearMedicare FFS programEvidence-based guidelinesScreening testRetrospective claims dataProstate cancer screeningPublic health issueMammography ratesFFS populationScreening trendsMedicare populationClaims dataGuideline publicationPatient preferences
2013
Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009.
Yang D, Gross C, Yu J. Changes in early- and late-stage colorectal cancer incidence during the era of screening: 1976-2009. Journal Of Clinical Oncology 2013, 31: 1522-1522. DOI: 10.1200/jco.2013.31.15_suppl.1522.Peer-Reviewed Original ResearchLate-stage colorectal cancerColorectal cancerCancer incidenceLate-stage colorectal cancer diagnosisEarly-stage colorectal cancerNon-screened populationColorectal cancer incidenceEnd Results (SEER) databaseColorectal cancer incidence dataAdults 50 yearsColorectal cancer diagnosisBreast cancer screeningLate-stage cancerEarly-stage cancerCancer incidence dataColorectal screeningResults databaseCancer screeningAdults 50Curable stageSubsequent diagnosisStage cancerDetects cancerNHS dataCancer
2012
A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival
Dosoretz A, Lester-Coll N, Yu J. A Decision Analysis to Assess the Value of Prostate Cancer Screening: A Shift in Focus From Prostate Cancer-specific Mortality to Distant Metastasis-free Survival. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s57. DOI: 10.1016/j.ijrobp.2012.07.355.Peer-Reviewed Original Research